Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Chemo's hidden toll: study probes life after endometrial cancer treatment

NCT ID NCT03466788

Knowledge-focused Sponsor: Centre Francois Baclesse Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at how chemotherapy impacts the quality of life of women treated for stage II or III endometrial cancer. Researchers asked 51 patients to fill out questionnaires about their physical, emotional, and social well-being at least two years after finishing treatment. The goal was to understand the long-term effects of chemotherapy beyond just survival.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help doctors understand the long-term quality-of-life effects of chemotherapy for endometrial cancer, guiding better treatment decisions.
What could go wrong
This is a small, completed observational study with only 51 participants, so results may not apply to all patients. It relies on self-reported questionnaires, which can be subjective.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

51 people

The number who actually took part.

Started

Mar 2018

Finished

Mar 2020

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: For all patients: * Women over 18 years of age, with histologically confirmed histologic type 1 or type 2 endometrial adenocarcinoma, with FIGO postoperative II or III stage operated between 2011 and 2015, with at least 2 years of follow-up compared to the last course of chemotherapy; * Recommended surgery such as hysterectomy and bilateral salpingo-oophorectomy, non-mandatory surgical nodal staging; * Pelvic radiotherapy +/- lumbar-aortic irradiation, optional brachytherapy; * No recurrence of endometrial cancer at baseline; * Absence of evolutionary neurological antecedent (multiple sclerosis, neurodegenerative pathology ...); * Absence of progressive psychiatric pathology (i.e. psychiatric hospitalization, bipolar disorder, schizophrenia, personality disorders ...); * No opposition to the collection of data; * Patient deemed fit to answer a written questionnaire. For the patient in the chemotherapy group - Chemotherapy after surgery that can be performed before or after radiotherapy Exclusion Criteria: For all patients: * Sarcoma or carcinosarcoma; * Stage FIGO I or IV; * Macroscopic tumor residue after surgery; * Recurrence of endometrial cancer or diagnosis of any other cancerous pathology after diagnosis of endometrial cancer (except non-melanotic skin tumors with complete excision), within 5 years; * drug use; * Abuse of alcohol. For the patient in the chemotherapy group * Chemotherapy before surgery; * Chemotherapy concomitant with radiotherapy For the patient in the group without chemotherapy \- Chemotherapy whether before or after surgery

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chemotherapy effect are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chemotherapy-induced toxicity endometrial cancer endometrium adenocarcinoma endometrium neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chemotherapy effect Endometrial cancer Quality of life

Contacts and locations

Locations

  • Centre Eugène Marquis

    Rennes, France

  • Centre François Baclesse

    Caen, 14076, France

  • Centre Henri Becquerel

    Rouen, France

  • Centre Oscar Lambret

    Lille, France

  • Institut Gustave Roussy

    Villejuif, 94805, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.